Covid-19
Moderna’s Phase III Covid-19 vaccine trial meets primary endpoints
In the trial, mRNA-1283 elicited a higher immune response against the SARS-CoV-2 virus, compared to mRNA-1273.222.
In the trial, mRNA-1283 elicited a higher immune response against the SARS-CoV-2 virus, compared to mRNA-1273.222.